Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD.
Coufal S, Kverka M, Kreisinger J, Thon T, Rob F, Kolar M, Reiss Z, Schierova D, Kostovcikova K, Roubalova R, Bajer L, Jackova Z, Mihula M, Drastich P, Tresnak Hercogova J, Novakova M, Vasatko M, Lukas M, Tlaskalova-Hogenova H, Jiraskova Zakostelska Z. Coufal S, et al. Among authors: lukas m. J Immunol Res. 2023 Jun 20;2023:1535484. doi: 10.1155/2023/1535484. eCollection 2023. J Immunol Res. 2023. PMID: 37383609 Free PMC article.
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study.
Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi T, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T. Resál T, et al. Among authors: lukas m. Inflamm Bowel Dis. 2024 May 2;30(5):768-779. doi: 10.1093/ibd/izad135. Inflamm Bowel Dis. 2024. PMID: 37542737 Free PMC article.
Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis.
Prokopič M, Gilca-Blanariux G, Lietava P, Trifan A, Pietrzak A, Ladic A, Brinar M, Turcan S, Molnár T, Bánovčin P, Lukáš M. Prokopič M, et al. Among authors: lukas m. Therap Adv Gastroenterol. 2023 Jun 12;16:17562848231174290. doi: 10.1177/17562848231174290. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37333465 Free PMC article. Review.
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Danese S. Peyrin-Biroulet L, et al. Among authors: lukas m. Aliment Pharmacol Ther. 2024 Jan;59(2):175-185. doi: 10.1111/apt.17751. Epub 2023 Nov 30. Aliment Pharmacol Ther. 2024. PMID: 38036946 Clinical Trial.
Update on the Role of Rifaximin in Digestive Diseases.
Dumitrascu DL, Bakulin I, Berzigotti A, Cravo M, Gombošová L, Lukas M, Pietrzak A, Remes-Troche JM, Romero-Gómez M, Balmori MA, Gonçalves TC, Hamzaoui L, Juricek R, Moreira L, Neubauer K, Surdea-Blaga T, Tikhonov IN, Trna J, Ianiro G, Ponziani FR, Gasbarrini A. Dumitrascu DL, et al. Among authors: lukas m. J Gastrointestin Liver Dis. 2023 Apr 1;32(1):92-109. doi: 10.15403/jgld-4871. J Gastrointestin Liver Dis. 2023. PMID: 37004222 Free article. Review.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R. Peyrin-Biroulet L, et al. Among authors: lukas m. BMC Gastroenterol. 2024 Mar 27;24(1):121. doi: 10.1186/s12876-024-03163-5. BMC Gastroenterol. 2024. PMID: 38539103 Free PMC article.
Daprodustat and Heart Failure in CKD.
Cunningham JW, Claggett BL, Lopes RD, McMurray JJV, Perkovic V, Carroll K, Hiemstra T, Khavandi K, Lukas MA, Ranganathan P, Shannon J, van Adelsberg J, Singh AK, Solomon SD. Cunningham JW, et al. Among authors: lukas ma. J Am Soc Nephrol. 2024 May 1;35(5):607-617. doi: 10.1681/ASN.0000000000000321. Epub 2024 Feb 22. J Am Soc Nephrol. 2024. PMID: 38383961 No abstract available.
361 results